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The need for reliever medication, such as the inhaled short-acting beta2-agonist (SABA) 
albuterol, along with day-time symptoms, night-time waking and activity limitations, is used 
to assess symptom control in asthma and to estimate the risk of future exacerbations (1). 
The inclusion of reliever inhaler use in assessments of asthma control in adults is based on 
evidence that overuse of SABA medication is associated with poor symptom control (2), 
increased risk of exacerbations (3, 4) and death from asthma (5, 6). Both national and 
international asthma guidelines use similar criteria to define SABA overuse (1, 7). In the 
GINA guideline, the use of a reliever inhaler for symptoms more than twice per week in the 
past 4 weeks is classified as partly controlled asthma and if symptoms and activity limitation 
due to asthma are also present is classified as uncontrolled asthma (1).  Excess SABA inhaler 
use greater than one 200-dose canister per month is a risk factor for exacerbations (1) and 
for death from asthma (5, 6). Overuse of reliever inhalers is a common problem in people 
with asthma, which is highlighted by the Medical Expenditure Panel Survey finding that 15% 
of the asthmatic population in the United States used more than one reliever inhaler 
canister per month (8).  In addition to increased albuterol use in patients with poorly 
controlled asthma, several demographic factors are associated with reliever inhaler overuse 
including male gender, black race, current smokers, lower educational level and lower 
income (8).  
 
In the current issue of The Journal Allergy and Clinical Immunology: In Practice, Gerald and 
colleagues (9) report the results of a study designed to describe the pattern of albuterol use 
on symptom and symptom free days and to identify characteristics associated with albuterol 
overuse in adolescents and adults with mild asthma previously enrolled in the American 
Lung Association-Asthma Clinical Research Centers’ Trial of Asthma Patient Education (TAPE) 
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(10).  A post hoc analyses was undertaken of demographics and daily diary data including 
albuterol use as well as generic and asthma specific quality of life, asthma control and 
clinical depression questionnaire scores. Participants were characterized as over-, expected-
, or under-users of albuterol based on albuterol use of ≥80% on symptom days and <20% on 
symptom free days. Four hundred and sixteen patients were recruited, of whom 212 (51%) 
were expected-users, 114 (27%) were over-users, and 90 (22%) were under-users of 
albuterol. The over-user group reported the greatest symptom burden, worst asthma 
control and lower asthma quality of life. Of particular interest was the unexpected finding 
that the frequency of albuterol use in the over-user group was greater on symptom free 
days (approximately half of the overuse) compared to symptomatic days.  The reason(s) for 
the excess use of albuterol on symptom-free days in not explained by the study, although 
possible factors might include psychological dependence on SABAs, heightened perception 
of symptoms or associated co-morbidities such as dysfunction breathing or psychiatric 
disorders such as anxiety or depression. Gerald and colleagues (9) propose that one of the 
goals of management of over-users should be to reduce inappropriate use of albuterol on 
symptom-free days since excessive beta2-agonist use has been associated with paradoxical 
adverse effects (11). 
 
Both anxiety and depression commonly occur in people with asthma (1). Depression is 
associated with worse asthma outcomes  and poor adherence with medication  (12). Using 
the Center for Epidemiological Studies-Depression threshold score of ≥16 to identify 
participants at risk of clinical depression, Gerald and colleagues (9) found that 32% of 
albuterol over-users were at risk of clinical depression compared to 17% of expected-users. 
The finding that the risk of depression in albuterol over-users was almost twice that found in 
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the expected-users emphasises the importance that clinicians should consider depression in 
patients with mild asthma who over-use albuterol.  
 
Although interesting, the study by Gerald and colleagues (9) has some limitations. The 
findings may not be generalizable to a ‘real-life’ population of patients with asthma that 
include a higher proportion of older subjects, current smokers, and subjects with a history of 
poor adherence with controller medications. The participants were mainly female and had 
mild disease and the pattern of reliever inhaler use may differ in males or in patients with 
severe disease. Also, the findings were from a short-term study lasting 4 weeks and may not 
reflect longer-term albuterol use. A further consideration is that self-reported inhaler use 
may not accurately reflect actual use, with over-users of SABAs tending to underreport their 
use and under-users of controller inhalers tending to overreport their use (13). Even if the 
participants in the study by Gerald and colleagues (9) underreported their use of albuterol, 
this is unlikely to affect the main conclusions on the pattern of reliever inhaler use. Finally, 
the psychological assessment did not include measures of anxiety status, psychosocial stress 
or personality traits which may influence reliever use. Further research is indicated to 
confirm and expand on the findings reported by Gerald and colleagues (9) by recruiting 
‘real-life’ populations of people with asthma as well as those with severe disease.  Future 
clinical studies should be undertaken for a longer duration, include objective measures of 
asthma outcomes, use electronic monitoring devices to measure inhaler use and include 
more detailed assessment of mental health including anxiety status. 
 
What are the clinical implications of the study by Gerald and colleagues (9) for the 
management of patients with asthma who overuse reliever medication? The preliminary 
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nature of the results temper any definitive conclusions on clinical management. 
Nevertheless, the findings suggest that when assessing patients with mild asthma suspected 
of reliever inhaler overuse, clinicians should consider that a proportion of albuterol use 
might be inappropriate, due to administration on symptom-free days and that depression 
may be an underlying co-morbidity. In the clinic, strategies to improve asthma control 
highlighted by reliever inhaler overuse include ensuring that the diagnosis of asthma is 
correct, starting or stepping-up controller therapy, improving adherence with controller 
therapy as well addressing co-morbidities, educational issues and self-management (1). 
Although depression may contribute to reliever inhaler over-use, poorly controlled asthma 
and poor adherence with controller medication, the best methods for treating psychological 
problems in patients with asthma are not clearly established (14). Of interest, relaxation 
therapy may decrease the use of reliever medication (14). Formal psychiatric assessment is 
indicated if clinical depression is suspected (1). Administrative-based asthma outreach 
programs are a novel intervention reported to reduce over-dispensing of SABA canisters 
without compromising asthma control (15). In conclusion, the study by Gerald and 
colleagues (9) on the pattern of overuse of albuterol in mild asthma and the association 
with depression provides a stimulus for further research into understanding the influence of 
psychological factors on asthma control and medication use and to developing effective 
strategies to manage reliever inhaler overuse. 
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